Emerging markets are reshaping the global pharmaceutical landscape. According to IQVIA, emerging markets are projected to account for over 30% of global pharmaceutical spending by 2026, with growth rates consistently outpacing developed markets.
Across developing countries, there is a staggering gap between healthcare needs and available resources. According to the latest WHO-World Bank report, 2 billion people worldwide face financial hardship due to healthcare costs, while the situation in sub-Saharan Africa is particularly acute: the continent imports a significant majority of its pharmaceuticals, leaving it highly vulnerable to global supply chain disruption